Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Assets (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Current Assets for 5 consecutive years, with $82.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 33.35% year-over-year to $82.9 million, compared with a TTM value of $82.9 million through Dec 2025, up 33.35%, and an annual FY2025 reading of $82.9 million, up 33.35% over the prior year.
  • Current Assets was $82.9 million for Q4 2025 at Aligos Therapeutics, down from $103.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $248.7 million in Q3 2021 and bottomed at $62.1 million in Q4 2024.
  • Average Current Assets over 5 years is $137.6 million, with a median of $130.7 million recorded in 2022.
  • The sharpest move saw Current Assets plummeted 55.95% in 2024, then surged 33.35% in 2025.
  • Year by year, Current Assets stood at $204.4 million in 2021, then tumbled by 34.67% to $133.5 million in 2022, then increased by 5.65% to $141.1 million in 2023, then crashed by 55.95% to $62.1 million in 2024, then skyrocketed by 33.35% to $82.9 million in 2025.
  • Business Quant data shows Current Assets for ALGS at $82.9 million in Q4 2025, $103.4 million in Q3 2025, and $127.9 million in Q2 2025.